DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

Antares Pharma, Inc. (NASDAQ: ATRS)



company name or ticker

Short Interest In Antares Pharma Decreases By 11%

Generic EpiPen Could Give These 2 Stocks A Jolt Of Adrenaline

Analyzing Antares Pharma Q3 2014 Earnings

Antares Pharma's (ATRS) CEO Eamonn Hobbs on Q3 2014 Results -- Earnings Call Transcript

Update: Antares Pharma Looks To Improve Intellectual Property

Comparative Analysis Reveals Undervalued Asset In Antares' Pipeline: First And Only Testosterone Aut

Comparative Analysis Reveals Undervalued Asset In Antares' Pipeline: First And Only Testosterone Auto-Injector

Unilife: A Medical Device Company Poised For Major Upside On New Revenue Streams

Antares Pharma: Significant Value Or Value Trap?

Antares: An Analysis Of FDA Briefing Documents For September 17th Advisory Committee Meeting On Test

Antares: An Analysis Of FDA Briefing Documents For September 17th Advisory Committee Meeting On Testosterone Replacement Products

5 Breakout Stocks Under $10 Set to Soar

See More Articles...